The main purpose of this study is to evaluate the presence of study drug LY3857210 in the brain measured by positron emission tomography (PET) with the radioligand \[18F\]-LY3818850 in healthy participants. The safety and tolerability of LY3857210 will also be evaluated. The study will last up to approximately 6 weeks for each participant and may include up to four visits to the study center.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Enrollment
10
Administered orally.
Invicro, Institute for Neurodegenerative Disorders
New Haven, Connecticut, United States
Change from baseline in brain receptor occupancy (RO) of LY3857210 measured by [18F]-LY3818850 PET scan
Change from baseline in brain RO of LY3857210 measured by \[18F\]-LY3818850 PET scan
Time frame: Baseline through study completion, up to approximately 6 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.